Michael Thomas Henderson's Net Worth
$82.4 Million
Who is Michael Thomas Henderson?
Michael Thomas Henderson has an estimated net worth of $82.4 Million. This is based on reported shares across multiple companies, which include BridgeBio Pharma, Inc., ARYA Sciences Acquisition Corp IV, Spyre Therapeutics, Inc., and Apogee Therapeutics, Inc..
SEC CIK
Michael Thomas Henderson's CIK is 0001779990
Past Insider Trading and Trends
2020 was Michael Thomas Henderson's most active year for acquiring shares with 27 total transactions. Michael Thomas Henderson's most active month to acquire stocks was the month of April. 2020 was Michael Thomas Henderson's most active year for disposing of shares, totalling 51 transactions. Michael Thomas Henderson's most active month to dispose stocks was the month of June. 2019 saw Michael Thomas Henderson paying a total of $119,000.00 for 180,767 shares, this is the most they've acquired in one year. In 2024 Michael Thomas Henderson cashed out on 125,000 shares for a total of $4,088,505.09, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
BridgeBio Pharma, Inc. (BBIO) Snapshot price: $30.7
Chief Business OfficerMichael Thomas Henderson owns 274,211 units of Common Stock which is worth $8,418,277.70. In the year 2019 Michael Thomas Henderson filed a total of 23 filings.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 15
| |||
Form 4
|
—
|
0
|
$26.29 | -$504,704.08 | 274.21K |
Scheduled
|
Dec 1
| ||
Form 4
| -0.30% | -784.00 |
$30.04 | -$23,548.54 | 261.4K |
Scheduled
|
Jun 3
| ||
Form 4
| +2.41% | 6.46K |
$22.90 | -$731,628.49 | 274.21K |
Scheduled
|
Nov 16
| ||
Form 4
|
—
|
0
|
$19.70 | -$373,057.65 | 267.75K |
Scheduled
|
Nov 2
| ||
Form 4
|
—
|
0
|
$19.81 | -$380,348.18 | 267.75K |
Scheduled
|
Oct 1
| ||
Form 4
|
—
|
0
|
$20.11 | -$397,788.12 | 267.75K |
Scheduled
|
Sep 18
| ||
Form 4
|
—
|
0
|
$14.45 | -$285,734.39 | 267.75K |
Scheduled
|
Sep 1
| ||
Form 4
| +2.82% | 7.35K |
$28.53 | -$155,773.80 | 267.75K |
Aug 16
| |||
Form 4
|
—
|
0
|
$13.77 | -$272,140.73 | 260.29K |
Scheduled
|
Aug 3
| ||
Form 4
|
—
|
0
|
$15.57 | -$308,101.26 | 260.29K |
Scheduled
|
Jul 1
| ||
Form 4
| -0.23% | -606.00 |
$30.01 | -$18,185.25 | 260.29K |
Scheduled
|
Jun 8
| ||
Form 4
| -0.98% | -2.58K |
$29.37 | -$75,911.65 | 261.68K |
Scheduled
|
Jun 1
| ||
Form 4
| +7.47% | 18.36K |
$1.05 | $19,283.25 | 264.27K |
May 26
| |||
Form 4
| +51.45% | 83.54K |
—
|
—
| 245.9K |
May 19
| |||
Form 4
| -0.89% | -1.46K |
$30.47 | -$44,493.35 | 162.36K |
Scheduled
|
May 5
| ||
Form 4
| -2.33% | -3.90K |
$29.52 | -$115,266.78 | 163.82K |
Scheduled
|
May 1 - May 4
| ||
Form 4
| -1.52% | -2.58K |
$26.94 | -$69,629.23 | 167.73K |
Scheduled
|
Apr 1
| ||
Form 4
| -2.28% | -3.98K |
$32.44 | -$128,965.21 | 170.31K |
Scheduled
|
Mar 2
| ||
Form 4
| -2.23% | -3.98K |
$34.90 | -$138,729.49 | 174.29K |
Scheduled
|
Feb 3
| ||
Form 4
| -2.18% | -3.98K |
$33.17 | -$131,861.08 | 178.26K |
Scheduled
|
Jan 2 - Jan 3
| ||
Form 4
|
∞
| 180.77K |
$17.00 |
—
| 180.77K |
Jul 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
ARYA Sciences Acquisition Corp IV (ARYD) No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 31
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Spyre Therapeutics, Inc. (AGLE) No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 14
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Apogee Therapeutics, Inc. (APGE) Snapshot price: $47.25
Chief Executive OfficerMichael Thomas Henderson owns 1,394,487 units of Common Stock which is worth $65,889,510.75. In the year 2023 Michael Thomas Henderson disposed a total of 95,000 shares of Apogee Therapeutics, Inc. equalling to $4,088,505.09.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -2.79% | -40.00K |
$47.62 | -$1,904,841.05 | 1.39M |
Scheduled
|
Sep 4
| ||
Form 4
| -2.71% | -40.00K |
$40.62 | -$1,624,764.04 | 1.43M |
Scheduled
|
Aug 7
| ||
Form 4
| -1.01% | -15.00K |
$37.26 | -$558,900.00 | 1.47M |
Scheduled
|
Jul 5
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 18
| |||
Form 3/A
|
—
|
0
|
—
|
—
|
0
| ||||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||